A Phase 1 Study of LY3039478 in Japanese Patients with Advanced Solid Tumors I6F-JE-JJCC
- Conditions
- Advanced Solid Tumor
- Registration Number
- JPRN-jRCT2080223309
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- Not specified
Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.
-In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.
-Performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
-Adequate organ function, including hematologic, hepatic, and renal.
-Estimated life expectancy of more than or equal to 12 weeks.
-Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.
-Have serious preexisting medical conditions.
-Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.
-Have an active bacterial, fungal, and/or known viral infection.
-Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method